SEATTLE — In this Healio Video Perspective from the ARVO meeting, Deepak Sambhara, MD, discusses central retinal thickness in patients with diabetic macular edema.
Sambhara used data from the phase 2/3 PHOTON study, which investigated aflibercept 8 mg in patients with diabetic macular edema, to track patients’ treatment journey, with baseline central retinal thickness as a surrogate for disease severity.
“Folks receiving 8 mg aflibercept who have the most swollen and presumably most diseased retinas and more circulating VEGF in their system really required that additional